fep blue glp-1 coverage 2026 π’ Two important dates for patients interested in medications: β July 1, β Medicare GLP-1 Bridge Program begins for eligible Medicare Part D beneficiaries. β October 1, 2026 β Zepbound 2025 FEP BLUE ZEPBOUND DRUG
Description
As more patients gain access, oral options could help expand effective glycemic and weight control to broader populations
9 Hormone replacement therapy (Mounjaro only) The same absorption issue applies to oral HRT
They showed that among patients treated with non-insulin antidiabetic drugs (with the exception of alpha-glucosidase inhibitors), GLP-1 receptor agonists had the lowest risk ratio for lung cancer (0.49, 95% CI: 0.410.59) compared to insulin regardless of histological type, gender, race, or smoking status
However, future studies are needed to explore the pathophysiology of GLP-1RAs in individuals with type 2 diabetes and NAFLD and to determine the optimal use of GLP-1RAs to prevent adverse CVEs
After placebo adjustments were taken into account, the average weight loss was around 10.9%
And like any tool, their effectiveness depends on how we use them
